Perifornical hypothalamic orexin and serotonin modulate the counterregulatory response to hypoglycemic and glucoprivic stimuli

Diabetes. 2015 Jan;64(1):226-35. doi: 10.2337/db14-0671. Epub 2014 Aug 11.

Abstract

Previous reports suggested an important role for serotonin (5-hydroxytryptamine [5-HT]) in enhancing the counterregulatory response (CRR) to hypoglycemia. To elucidate the sites of action mediating this effect, we initially found that insulin-induced hypoglycemia stimulates 5-HT release in widespread forebrain regions, including the perifornical hypothalamus (PFH; 30%), ventromedial hypothalamus (34%), paraventricular hypothalamus (34%), paraventricular thalamic nucleus (64%), and cerebral cortex (63%). Of these, we focused on the PFH because of its known modulation of diverse neurohumoral and behavioral responses. In awake, behaving rats, bilateral PFH glucoprivation with 5-thioglucose stimulated adrenal medullary epinephrine (Epi) release (3,153%) and feeding (400%), while clamping PFH glucose at postprandial brain levels blunted the Epi response to hypoglycemia by 30%. The PFH contained both glucose-excited (GE) and glucose-inhibited (GI) neurons; GE neurons were primarily excited, while GI neurons were equally excited or inhibited by 5-HT at hypoglycemic glucose levels in vitro. Also, 5-HT stimulated lactate production by cultured hypothalamic astrocytes. Depleting PFH 5-HT blunted the Epi (but not feeding) response to focal PFH (69%) and systemic glucoprivation (39%), while increasing PFH 5-HT levels amplified the Epi response to hypoglycemia by 32%. Finally, the orexin 1 receptor antagonist SB334867A attenuated both the Epi (65%) and feeding (47%) responses to focal PFH glucoprivation. Thus we have identified the PFH as a glucoregulatory region where both 5-HT and orexin modulate the CRR and feeding responses to glucoprivation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Astrocytes / cytology
  • Astrocytes / metabolism
  • Benzoxazoles / pharmacology
  • Blood Glucose / metabolism
  • Cells, Cultured
  • Diabetes Mellitus, Type 1 / metabolism
  • Diabetes Mellitus, Type 1 / physiopathology
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetes Mellitus, Type 2 / physiopathology
  • Fornix, Brain / metabolism*
  • Hypoglycemia / metabolism*
  • Hypoglycemia / physiopathology
  • Hypothalamus / metabolism*
  • Intracellular Signaling Peptides and Proteins / metabolism*
  • Male
  • Midline Thalamic Nuclei / metabolism
  • Naphthyridines
  • Neurons / cytology
  • Neurons / metabolism
  • Neuropeptides / metabolism*
  • Orexins
  • Paraventricular Hypothalamic Nucleus / metabolism
  • Rats, Sprague-Dawley
  • Receptors, Neuropeptide / antagonists & inhibitors
  • Serotonin / metabolism*
  • Urea / analogs & derivatives
  • Urea / pharmacology
  • Ventromedial Hypothalamic Nucleus / metabolism

Substances

  • 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea
  • Benzoxazoles
  • Blood Glucose
  • Intracellular Signaling Peptides and Proteins
  • Naphthyridines
  • Neuropeptides
  • Orexins
  • Receptors, Neuropeptide
  • Serotonin
  • Urea